Group 1 - Daikin Heavy Industries' subsidiary signed a contract worth approximately 1.339 billion yuan for an offshore wind farm project in Europe, accounting for 35.41% of the company's audited revenue for 2024 [1] Group 2 - Zhaoyi Innovation announced that several board members and senior management plan to reduce their holdings by a total of 249,000 shares, due to personal financial needs, with the reduction period set from December 15, 2025, to March 14, 2026 [2] Group 3 - Jushi Chemical received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws, while the company's operations continue normally [3][6] Group 4 - Chaozhuo Aerospace announced a stock suspension due to major matters being planned by its controlling shareholders, which may lead to a change in control [4] Group 5 - Heng Rui Medicine received approval for clinical trials of SHR-1139 injection, a biopharmaceutical with no similar products approved for sale domestically or internationally, with a cumulative R&D investment of approximately 100.13 million yuan [5] Group 6 - Huayou Pharmaceutical's HYP-6589 tablet for treating advanced non-small cell lung cancer received a clinical trial application acceptance notice, with no similar products approved for sale [8] Group 7 - Renfu Pharmaceutical's application for the marketing license of Dexamethasone L-amphetamine capsules was accepted, aimed at treating ADHD, with a cumulative R&D investment of approximately 90 million yuan [10] Group 8 - Huibo Group won a bid for a 1.596 billion yuan project for the restoration of an oil field in Iraq [10]

2家上市公司，公告被证监会立案。 11月21日晚，聚石化学（688669）公告称，公司于2025年11月21日收到中国证监会下发的《立案告知书》，因公司涉嫌信息披露违法违规，中国证监会决定对 公司立案。 聚石化学称，目前公司各项经营活动和业务均正常开展，将积极配合中国证监会的相关工作，并及时履行信息披露义务。 同日，豪尔赛（002963）公告，公司于近日收到中国证监会下发的《立案告知书》，因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和 国行政处罚法》等法律法规，中国证监会对公司进行立案。 值得注意的是，豪尔赛曾于2025年7月29日公告，公司实际控制人之一戴宝林为支持戴聪棋作为上市公司控股股东暨实际控制人行使股东权利，更好地行使公司经 营管理及重大事项决策权，与戴聪棋签署了《关于豪尔赛科技集团股份有限公司之表决权委托协议》，将持有的公司3512.84万股股份（占公司总股本的 23.36%）对应的全部表决权、召集权、提名和提案权、参会权、监督建议权以及除收益权和股份转让权等财产性权利之外的其他权利独家委托给戴聪棋行使。本 次表决权委托后，公司控股股东、实际控制人变更为戴聪棋和刘清梅；戴宝林、 ...

Core Points - Haosai has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure regulations [2][4] - The company's actual controller, Dai Baolin, has been arrested for alleged unit bribery, leading to further scrutiny of the company's operations [5][6] Group 1: Investigation Details - On November 21, Haosai announced it received a notice of investigation from the CSRC due to suspected information disclosure violations [2] - The investigation follows Dai Baolin's arrest by public security authorities for alleged unit bribery, which has raised concerns about the company's governance and internal controls [5][6] Group 2: Company Operations - Haosai stated that it will actively cooperate with the investigation and that its business operations are currently normal and orderly [4] - The company has been under negative scrutiny since December of the previous year, with regulatory bodies highlighting deficiencies in its information disclosure practices [5][6] Group 3: Regulatory Actions - The Beijing Securities Regulatory Bureau issued a warning letter to Haosai for failing to fulfill its information disclosure obligations [6][7] - The Shenzhen Stock Exchange also sent a regulatory letter to Haosai and its responsible personnel, urging strict compliance with relevant laws and regulations regarding information disclosure [8] Group 4: Company Profile - Haosai's main business includes precision stamping molds and metal structural components for new energy vehicles, fuel vehicles, energy storage equipment, and communication devices [8] - As of November 21, Haosai's stock price was reported at 16.21 yuan per share, with a total market value of 2.437 billion yuan [8]

Core Viewpoint - 聚石化学 and 豪尔赛 are both under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact their operations and investor confidence [1][5]. Company Overview - 聚石化学 specializes in the research, production, and sales of new chemical materials, with products including modified plastic particles, automotive profiles, optical materials, and flame retardants, among others [3]. - 豪尔赛 focuses on technology innovation, developing smart lighting, smart cultural tourism, and smart urban areas, along with a digital twin integration network platform [7]. Financial Performance - 聚石化学 reported a revenue of 986.58 million yuan for Q3 2025, a decrease of 0.81% year-on-year, with a net profit of 2.89 million yuan [4]. - 豪尔赛 achieved a revenue of 106.94 million yuan for Q3 2025, an increase of 31.34% year-on-year, with a net profit of 740.11 thousand yuan, reflecting a significant growth of 599.72% [8].

Core Viewpoint - Two A-share companies, 聚石化学 and 豪尔赛, have been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2][5]. Group 1: 聚石化学 (688669) - On November 21, 2025, 聚石化学 received a notice from the CSRC regarding the investigation for suspected information disclosure violations [2]. - The company reported a revenue of 987 million yuan in Q3 2025, a year-on-year decrease of 0.81%, with a net profit attributable to shareholders of 2.89 million yuan [4]. - 聚石化学 specializes in the research, production, and sales of new chemical materials, with products used in various industries including automotive, electronics, and healthcare [4]. Group 2: 豪尔赛 (002963) - 豪尔赛 also received a notice from the CSRC for suspected information disclosure violations [5]. - The company reported a revenue of 107 million yuan in Q3 2025, a year-on-year increase of 31.34%, and a net profit attributable to shareholders of 7.40 million yuan, a significant increase of 599.72% [8]. - 豪尔赛 focuses on technology innovation in areas such as smart lighting and digital twin networks, and has been under scrutiny due to previous issues related to corporate governance and internal controls [7][8].

公司同时提醒，指定信息披露媒体为《证券时报》和巨潮资讯网（www.cninfo.com.cn），公司发布的 信息以上述指定媒体刊登的内容为准，敬请广大投资者理性投资，注意风险。 点击查看公告原文>> 登录新浪财经APP 搜索【信披】查看更多考评等级 豪尔赛科技集团股份有限公司（证券代码：002963，证券简称：豪尔赛）11月21日发布公告称，公司近 日收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》，因涉嫌信息披露违 法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等相关法律法规，中国证监会 决定对公司进行立案调查。 公告显示，公司将积极配合中国证监会的立案调查工作，并严格按照相关法律法规的规定和监管要求及 时履行信息披露义务。针对本次立案事项，豪尔赛表示，目前公司各项经营活动正常有序开展，本次立 案不会对公司经营和管理造成重大影响。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法 ...

Core Viewpoint - Haosai (002963) has received a notice of investigation from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, but the company asserts that its operations remain normal and orderly, and the investigation will not significantly impact its management and operations [1] Group 1 - On November 21, Haosai announced the receipt of the CSRC's "Notice of Investigation" [1] - The investigation is due to alleged violations of information disclosure regulations [1] - Haosai's stock price fell by 5.32% to 16.21 yuan at market close on the day of the announcement [1]

盘面上，截至 今日 收盘， 豪尔赛跌5.32%，报16.21元。 编辑 ｜心一 11月21日，豪尔赛（002963）公告称， 公司于近日收到中国证监会下发的《立案告知书》，因涉嫌 信息披露违法违规，中国证监会对公司进行立案。 豪尔赛表示， 目前，公司各项经营活动正常有序开展，本次立案不会对公司经营和管理造成重大影 响。 ...

Regulatory Actions - Haosai is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, but the company states that its operations remain normal and the investigation will not significantly impact management [2] - Central Plaza and its executives received a warning letter from the Jiangsu Securities Regulatory Bureau for failing to timely disclose significant litigation progress, which led to inaccurate financial reporting [3] - Guolian Aquatic received a warning letter from the Guangdong Securities Regulatory Bureau for non-operating fund occupation by its controlling shareholder, which was not disclosed in a timely manner [9] Corporate Actions - Jiarong Technology is planning a major asset restructuring and has suspended trading of its shares, expected to last no more than 10 trading days [4] - Maiwei Co. announced a debt restructuring totaling 371 million yuan, with an expected loss of 85.465 million yuan, aimed at improving cash flow and reducing receivables risk [5] - New World plans to use up to 850 million yuan of idle fundraising to purchase financial products or deposits, with a total of 575 million yuan already invested in such products [6] Legal Matters - Sunshine Nuohuo's lawsuit against Hengsheng Pharmaceutical has entered the second instance, with the original claim amounting to 20 million yuan and a counterclaim of 7.4073 million yuan [8] Product Development - Huyou Pharmaceutical's HYP-6589 tablet has received acceptance for clinical trial applications for treating advanced non-small cell lung cancer [7] - Renfu Pharmaceutical's application for the marketing license of a new ADHD treatment has been accepted, with no similar products currently available in the domestic market [10] Strategic Partnerships - Jindi Co. signed a strategic cooperation letter of intent with Dongpei Co. to explore collaboration on humanoid robot harmonic reducer assemblies and key components [11] Share Buybacks and Holdings - Yuyuan Co. has repurchased 1 million A-shares for a total of approximately 5.3864 million yuan as part of a buyback plan [12] - Yuheng Pharmaceutical's executives increased their holdings by 1.12%, acquiring a total of 25 million shares [13] Major Contracts - Huayou Huibo has been awarded a contract worth 225 million USD for the Iraq NaftKhana oilfield project, which is expected to significantly impact future earnings [16] - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, representing 35.41% of the company's expected annual revenue [17]

格隆汇11月21日丨豪尔赛(002963.SZ)公布，近日收到中国证券监督管理委员会（简称"中国证监会"）下 发的《立案告知书》，因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行 政处罚法》等法律法规，中国证监会对公司进行立案。 ...